Cytosorbents Co. (NASDAQ:CTSO) Stake Boosted by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of Cytosorbents Co. (NASDAQ:CTSO) by 7.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 467,058 shares of the medical research company’s stock after purchasing an additional 32,415 shares during the quarter. Geode Capital Management LLC owned 0.85% of Cytosorbents worth $701,000 at the end of the most recent reporting period.

Separately, Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the third quarter worth $51,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CTSO shares. StockNews.com started coverage on Cytosorbents in a research report on Sunday, January 5th. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Friday, January 3rd. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Cytosorbents has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $0.94 on Friday. The firm has a market capitalization of $51.27 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents Co. has a one year low of $0.70 and a one year high of $1.59. The stock’s fifty day moving average is $0.92 and its 200-day moving average is $1.03.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.